Key Highlights
- Shares of Alcon surged over 3% following an upgrade to annual earnings projections
- Expected tariff impact for 2026 reduced to $40M-$90M from previous forecast of $100M-$150M
- Projected $60M refund from U.S. authorities prompted the tariff outlook adjustment
- Company increased core diluted EPS forecast to 12%-15% expansion, marking its second upward revision this year
- Second-quarter revenue reached $2.78B, exceeding projections, while adjusted EPS hit $0.84 versus $0.75 consensus
Shares of the Swiss-American eye care specialist Alcon experienced gains exceeding 3% on Monday after management elevated its annual earnings forecast and significantly lowered its projected tariff-related expenses for 2026.
The equity traded up more than 3% as of 08:24 GMT in response to the news.
The company’s updated projection calls for core diluted earnings per share to expand between 12% and 15% for the current year. This represents an improvement from the previously announced 10% to 13% growth range issued in May, and constitutes the second time Alcon has upgraded this particular metric in 2026.
Additionally, Alcon broadened its expectations for core operating profit margin expansion. The revised outlook anticipates margin growth of 90 to 190 basis points for the complete fiscal year, an increase from the earlier projection of 70 to 170 basis points.
The company maintained its existing revenue growth projection, keeping full-year net sales guidance steady at 5% to 7% growth on a constant currency basis.
Tariff Exposure Reduced by Nearly Half
Among the most significant elements of Monday’s announcement was the substantial reduction in anticipated tariff costs. Alcon’s updated estimate places the full-year tariff impact between $40 million and $90 million, representing a considerable decrease from the previously forecasted range of $100 million to $150 million.
This revision stems primarily from an expected government refund of approximately $60 million from U.S. authorities.
The United States represents a crucial market for the eye care manufacturer, generating 45% of total net sales during the initial six months of the year. Additionally, the majority of Alcon’s primary manufacturing operations are located domestically, which helps mitigate the supply chain vulnerabilities that affect many multinational corporations.
Second Quarter Performance Exceeds Expectations Across Key Metrics
Net sales for the second quarter totaled $2.78 billion, representing an increase from $2.58 billion reported during the comparable period last year. This performance slightly exceeded analyst estimates compiled by LSEG.
The company’s adjusted earnings per share reached $0.84 for the quarter, surpassing the IBES consensus estimate of $0.75.
Company executives attributed the stronger-than-expected results to successful introductions of new products and effective commercial strategy implementation.
The core operating margin for the second quarter registered at 20.6%.
Both the upgraded guidance and revised tariff outlook were disclosed alongside the second-quarter financial results, which the company published late Monday.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
